A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

NCT ID: NCT04631016

Last Updated: 2025-02-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 137 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-14
• Study Completion Date: 2023-11-13

Brief Summary

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

Detailed Description

Study D9180C00002 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy and safety of MEDI3506 in adult participants with moderate to severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

Approximately 85 sites globally will participate in this study. Approximately 144 participants will be randomized to 2 treatment groups in a 1:1 ratio to receive MEDI3506 or placebo.

Conditions

Chronic Obstructive Pulmonary Disease (COPD); Chronic Bronchitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Tozorakimab

Participants received 7 doses of subcutaneous (SC) tozorakimab Dose Level 1 injection once every 4 weeks (Q4W).

Group Type: EXPERIMENTAL

Tozorakimab

Intervention Type: DRUG

Participants will receive SC injection of tozorakimab as stated in arm description.

Placebo

Participants received 7 doses of SC placebo injection matched to tozorakimab once Q4W.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Participants will receive SC injection of placebo as stated in arm description.

Interventions

Tozorakimab

Participants will receive SC injection of tozorakimab as stated in arm description.

Intervention Type: DRUG

Placebo

Participants will receive SC injection of placebo as stated in arm description.

Intervention Type: OTHER

Other Intervention Names

MEDI3506

Eligibility Criteria

Inclusion Criteria

• Provision of informed consent.
• Participant must be 40 to 80 years of age inclusive, at the time of signing the informed consent form (ICF).
• Participants who are current or ex-smokers with a tobacco history of >= 10 pack-years.
• Participants who have a documented history of COPD for at least 1 year.
• Participants who have a post-BD FEV1/FVC < 0.70 and a post-BD FEV1 >= 20% and < 80% predicted normal value at screening. Centralized spirometry will be used for this criteria assessment.
• Participants who have a physician confirmed participant history of chronic bronchitis as defined as presence of cough and sputum on most days for >= 3 months/year in at least the 2 year period immediately prior to study visit 1 (SV1) (Screening).
• Participants who have an average BCSS score of >= 2 in cough and >= 2 in sputum domains assessed over 14 days preceding SV3.
• Participants who have a documented stable regimen of dual therapy or triple therapy for >= 3 months prior to enrolment; there should have been no change in treatment after the previous exacerbation prior to entering into the study. Where dual therapy consists of inhaled corticosteroids (ICS) + long-acting beta 2 agonist (LABA) or LABA + long-acting muscarinic receptor antagonist (LAMA), and triple therapy consists of ICS + LABA + LAMA.
• Participants who have a documented history of >= 1 moderate or severe AECOPD requiring systemic corticosteroids and/or antibiotics for at least 3 days duration (or 1 injection of depot formulation), or hospitalization for reason of AECOPD in the previous 24 months.
• Body mass index within the range 18 to 40 kg/m^2 (inclusive).
• Female participants of childbearing potential, must have negative pregnancy tests.
• Male and female participants must follow protocol contraceptive guidance.

Exclusion Criteria

• Participants with a positive diagnostic nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at screening. Participants with mild or asymptomatic disease could be rescreened.
• Participants with a significant coronavirus disease 2019 (COVID-19) illness within 6 months of enrolment.
• As judged by the investigator, any evidence of any active medical or psychiatric condition or other reason which in the investigator's opinion makes it undesirable for the participant to participate in the study.
• Current or past diagnosis of asthma which persisted beyond age of 25 years.
• Clinically important pulmonary disease other than COPD, radiological findings, and/or laboratory findings suggestive of a respiratory disease other than COPD that is contributing to the participant's respiratory symptoms.
• Increased pre-BD FEV1 at randomization visit (SV3) compared to Screening SV1 of >= 400 mL or >= 25% of SV1 FEV1.
• Any other clinically relevant abnormal findings on physical examination, laboratory testing; or chest CT scan, which in the opinion of the investigator or medical monitor may compromise the safety of the participant in the study or interfere with evaluation of the study intervention or reduce the participant's ability to participate in the study.

Chest CT scan findings requiring further investigation or repeat CT surveillance before SV14.

• A family history of heart failure.
• A LVEF < 45% measured by echocardiogram.
• History of a clinically significant infection (viral, bacterial, or fungal) within 4 weeks.
• History of, or a reason to believe a participant has a history of, drug or alcohol abuse within the past 2 years prior to screening.
• Participants with a recent history of, or who have a positive test for, infective hepatitis or unexplained jaundice, or participants who have been treated for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
• Evidence of active or untreated latent tuberculosis (TB).
• Change in smoking status in 12 weeks prior to enrolment or intention to change smoking status between enrolment and end of follow-up.
• Participants currently receiving background therapy that is not approved by regulatory authorities in the country of study for COPD are not eligible for the study.
• History of treatment with cardiotoxic medications (eg, as part of cancer therapy) including thiazolidinedione's.
• Treatment with broad spectrum antibiotic within 4 weeks prior to randomization (Day 1).
• Receiving any of the prohibited concomitant medications as specified in the clinical study protocol (CSP).
• Inability to perform technically acceptable spirometry.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Sheffield, Alabama, United States

Research Site

Newport Beach, California, United States

Research Site

Newark, Delaware, United States

Research Site

Kissimmee, Florida, United States

Research Site

Ormond Beach, Florida, United States

Research Site

Winter Park, Florida, United States

Research Site

Lakeside Park, Kentucky, United States

Research Site

White Marsh, Maryland, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

New Bern, North Carolina, United States

Research Site

Columbus, Ohio, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

North Charleston, South Carolina, United States

Research Site

Spartanburg, South Carolina, United States

Research Site

Boerne, Texas, United States

Research Site

Nedlands, , Australia

Research Site

South Brisbane, , Australia

Research Site

Spearwood, , Australia

Research Site

Tarragindi, , Australia

Research Site

St. John's, Newfoundland and Labrador, Canada

Research Site

Ajax, Ontario, Canada

Research Site

Québec, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Sherbrooke, Quebec, Canada

Research Site

Trois-Rivières, Quebec, Canada

Research Site

Brno, , Czechia

Research Site

Olomouc, , Czechia

Research Site

Písek, , Czechia

Research Site

Prague, , Czechia

Research Site

Rokycany, , Czechia

Research Site

Aalborg, , Denmark

Research Site

Hvidovre, , Denmark

Research Site

København NV, , Denmark

Research Site

Næstved, , Denmark

Research Site

Odense C, , Denmark

Research Site

Bamberg, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Darmstadt, , Germany

Research Site

Hanover, , Germany

Research Site

Leipzig, , Germany

Research Site

Mainz, , Germany

Research Site

Marburg, , Germany

Research Site

Balassagyarmat, , Hungary

Research Site

Budapest, , Hungary

Research Site

Debrecen, , Hungary

Research Site

Edelény, , Hungary

Research Site

Gödöllő, , Hungary

Research Site

Hajdúnánás, , Hungary

Research Site

Pécs, , Hungary

Research Site

Ashkelon, , Israel

Research Site

Jerusalem, , Israel

Research Site

Jerusalem, , Israel

Research Site

Rehovot, , Israel

Research Site

Eindhoven, , Netherlands

Research Site

Rotterdam, , Netherlands

Research Site

Zutphen, , Netherlands

Research Site

Auckland, , New Zealand

Research Site

Christchurch, , New Zealand

Research Site

Tauranga, , New Zealand

Research Site

Wellington, , New Zealand

Research Site

Bialystok, , Poland

Research Site

Bydgoszcz, , Poland

Research Site

Katowice, , Poland

Research Site

Krakow, , Poland

Research Site

Poznan, , Poland

Research Site

Tarnów, , Poland

Research Site

Wroclaw, , Poland

Research Site

Cape Town, , South Africa

Research Site

Durban, , South Africa

Research Site

Johannesburg, , South Africa

Research Site

Tygervalley, , South Africa

Research Site

Alzira, , Spain

Research Site

Madrid, , Spain

Research Site

Málaga, , Spain

Research Site

Mérida, , Spain

Research Site

Salamanca, , Spain

Research Site

Santander, , Spain

Research Site

Zaragoza, , Spain

Research Site

Kaohsiung City, , Taiwan

Research Site

Kaohsiung City, , Taiwan

Research Site

Taipei, , Taiwan

Research Site

Taipei, , Taiwan

Research Site

Taoyuan, , Taiwan

Research Site

Bradford, , United Kingdom

Research Site

Bristol, , United Kingdom

Research Site

Edinburgh, , United Kingdom

Research Site

London, , United Kingdom

Research Site

Newcastle upon Tyne, , United Kingdom

Countries

United States; Australia; Canada; Czechia; Denmark; Germany; Hungary; Israel; Netherlands; New Zealand; Poland; South Africa; Spain; Taiwan; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9180C00002&amp;attachmentIdentifier=8cec254d-22b5-4324-a9c7-3a1c85961135&amp;fileName=d9180c00002-study-CSR-synopsis-Redacted.pdf&amp;versionIdentifier=

Redacted CSR synopsis

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9180C00002&amp;attachmentIdentifier=e07af4eb-a32b-4902-be1c-366581ef5363&amp;fileName=D9180C00002_-_Statistical_Analysis_Plan-Redacted.pdf&amp;versionIdentifier=

Redacted SAP

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9180C00002&amp;attachmentIdentifier=0b28d766-11db-42c1-a3d3-a43b0d7d053c&amp;fileName=D9180C00002_-_Protocol_Amendment-Redacted.pdf&amp;versionIdentifier=

Redacted CSP

Other Identifiers

2020-000571-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D9180C00002

Identifier Type: -

Identifier Source: org_study_id